Volume | 970,002 |
|
|||||
News | - | ||||||
Day High | 0.3999 | Low High |
|||||
Day Low | 0.3761 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inovio Pharmaceuticals Inc New | INO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3761 | 0.3761 | 0.3999 | 0.389 | 0.3797 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,453 | 970,002 | $ 0.3882836 | $ 376,636 | - | 0.3705 - 2.61 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:56:51 | 92 | $ 0.39 | USD |
Inovio Pharmaceuticals Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
104.23M | 268.07M | - | 10.26M | -279.82M | -1.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inovio Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.394 | 0.3999 | 0.3705 | 0.3838461 | 1,550,761 | -0.0052 | -1.32% |
1 Month | 0.4424 | 0.49 | 0.3705 | 0.4187606 | 2,189,337 | -0.0536 | -12.12% |
3 Months | 0.4985 | 0.609 | 0.3705 | 0.4690935 | 2,517,245 | -0.1097 | -22.01% |
6 Months | 0.877 | 0.9977 | 0.3705 | 0.5870714 | 6,421,027 | -0.4882 | -55.67% |
1 Year | 1.79 | 2.61 | 0.3705 | 1.10 | 5,734,154 | -1.40 | -78.28% |
3 Years | 11.93 | 19.00 | 0.3705 | 6.09 | 6,818,497 | -11.54 | -96.74% |
5 Years | 5.60 | 35.50 | 0.3705 | 10.44 | 8,930,652 | -5.21 | -93.06% |
Inovio Pharmaceuticals Description
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. |